Hadhramaut Sidr Extract vs. Multidrug-Resistant Biofilms
Antimicrobial and antioxidant potential of Yemeni Sidr honey against multidrug-resistant pathogens — in vitro and in silico studies
Alhadrami HA, Sayed AM, Hassan HM, Rateb ME, Taher MA — Future Journal of Pharmaceutical Sciences (2025)
In vitro biofilm and growth-inhibition assays across eight resistant bacterial and fungal strains using 200 µg/mL honey extracts, paired with computational docking.
Sample tested: Hadhramaut Governorate, Yemen (November 2021 harvest)
Measured Observation
Hadhramaut Sidr extract inhibited Pseudomonas aeruginosa biofilm formation by 68.2% (vs. 55.2% for imipenem) and Candida albicans by 62.6% (vs. 56.1% for fluconazole), with 94.2% growth inhibition on Staphylococcus aureus.
Methodology Notes
- Researchers prepared concentrated ethanol extracts from a single Hadhramaut Sidr collection rather than testing raw whole honey directly.
- In silico docking flagged chrysin, ellagic acid, and caffeic acid as candidate phenolic compounds.
Methodological Limitations & Caveats
- Concentrated ethanol extracts (200 µg/mL) do not represent dietary honey intake.
- Conducted strictly in vitro and in silico with no animal or human clinical testing.
- Based on one collection sample; harvest-to-harvest variance was not measured.